QUAY STEVEN C 4

What Happened

• Steven C. Quay, President, CEO and Director of Atossa Therapeutics (ATOS), received equity awards on January 20, 2026: 325,203 restricted stock units (RSUs) and 950,000 stock options. The RSUs were granted at $0.00 (award) and will convert to one share per RSU upon vesting. The 950,000 options were reported as a derivative acquisition with an aggregate strike amount of $572,850 (exercise price $0.603 per share, the closing price on Jan 20, 2026). These are grants/awards (not open-market purchases or sales).

Key Details

• Transaction date: January 20, 2026; Form filed January 22, 2026 (timely filing).
• RSUs: 325,203 RSUs granted; each RSU equals a contingent right to one share; vesting: 1 year from grant (per footnote).
• Options: 950,000 options issued; exercise price $0.603 per share; options vest quarterly over 24 months starting Jan 20, 2026 (subject to continued service).
• Shares owned after transaction: Not disclosed on this Form 4.
• Related-party note: Ensisheim Partners, LLC is wholly owned by Quay and Dr. Shu‑Chih Chen; they share voting/investment power and Quay disclaims beneficial ownership except to the extent of his pecuniary interest.
• Filing status: Not marked late.

Context

• These transactions are compensation grants (RSUs and stock options) rather than purchases or sales; RSUs convert to shares only upon vesting, and the options vest over two years subject to continued service—so they are not immediately sellable common stock. Such awards are common forms of executive compensation and do not by themselves indicate a buy/sell signal.